Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis
June 06, 2014 |
Aradigm Corporation (Aradigm) announced on June 3 that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).
“I am pleased that our team has achieved this very important milestone, which also further strengthens our financial position,” said Nancy Pecota, Chief Financial Officer, Aradigm.
Bronchiectasis is a severe, chronic and rare disease characterized by abnormal dilatation of the bronchi and bronchioles, frequently associated with chronic lung infections. It is often a consequence of a vicious cycle of inflammation, recurrent lung infections, and bronchial wall damage.
Non-CF BE represents an unmet medical need with high morbidity and mortality that affects more than 110,000 people in the U.S. and over 200,000 people in Europe. There is currently no drug approved for the treatment of this condition.
Please click here to read the full release.